Adaptin Bio APTN
OTC APTN
$6.27 +0.00 (+0.00%)
At close: Aug 19, 2026 · 4:00 PM EDT

Adaptin Bio (APTN) Return on Capital Employed [ROCE] (2025)

Updated

Adaptin Bio (APTN) recorded Return on Capital Employed [ROCE] of -362.04% in Q2 2025, up 350.48 percentage points from the prior quarter.

Analysis

Adaptin Bio (APTN) Return on Capital Employed [ROCE] (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.52%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 21.60%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.65%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.91%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 17.37%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.15%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 11.32%
10 Adaptin Bio 56.76 Mn 54.75 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -362.04%
Mar 31, 2025 -712.52%
API Access

Adaptin Bio Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=APTN&period=max&api_key=YOUR_API_KEY